The information available on the effects of maternal dietary habits on systemic inflammation and adverse maternal outcomes is limited. We aimed to evaluate whether Dietary Inflammatory Index (DII) score during pregnancy is associated with maternal body mass index (BMI), Mediterranean diet (MD) adherence, and perinatal outcomes. At 19–23 weeks’ gestation, 1028 pregnant women were recruited. Dietary information was assessed using a 17-item dietary score to evaluate MD adherence and a validated 151-item food frequency questionnaire. DII score was established according to 33 food and nutritional proinflammatory and anti-inflammatory items. Participants were distributed into tertiles according to the DII score, where a lower DII score (first tertile) represented an anti-inflammatory diet and the third tertile represented the more proinflammatory diet. Maternal characteristics and perinatal outcomes were collected, and newborns’ birthweight percentiles were calculated. Adjusted logistic regression models were used to assess the association of the DII score with maternal and perinatal characteristics, setting the third tertile as the reference group. Women in the third tertile showed lower adherence to MD score compared to the first tertile: median (25th to 75th percentile) 9 (7 to 11) vs. 6 (4.25 to 8), p < 0.001. The proinflammatory diet was significantly associated with a higher maternal pre-pregnancy BMI (adjusted β = 0.88; 95% CI: 0.31 to 1.45) and lower newborn’s birthweight percentile (adjusted β = −9.84th; 95% CI: −19.6 to −0.12). These data show that a proinflammatory diet profile may be associated with maternal overweight and fetal undergrowth.
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
Background: In the non‐ETSfusion of prostate cancer (PCa) pathway,SPOPmutations emerge as a distinct oncogenic driver subclass. BothSPOPdownregulation and mutation can lead toSPOPtarget stabilization promoting dysregulation of key regulatory pathways.CHD1gene is commonly deleted in PCa.CHD1loss significantly co‐occurs withSPOPmutations, resulting in a PCa subclass with increased AR transcriptional activity and with a specific epigenetic pattern.Methods: In this study, SPOP alterations at mutational and protein levels andCHD1copy number alterations have been analyzed and correlated with ERG and PTEN protein expression and with the clinical pathological features of the patients.Results: SPOP protein loss has been detected in 42.9% of the cases, and it has been strongly associated with PTEN protein loss (p < .001).CHD1gene loss has been detected in 24.5% andSPOPmutations in 5.9% of the cases. Loss ofCHD1has been strongly associated withSPOPmutations (p = .003) and has shown a trend to be associated with ERGwtcancers (p = .08).The loss of SPOP protein (p = .01) and the combination of PTEN and SPOP protein loss (p = .002) were both statistically more common in grade group 5 cancers, with a prevalence of 60% and 37.5%, respectively. Furthermore, SPOP loss/PTEN loss and SPOPwt/PTEN loss phenotypes were strongly associated with extraprostatic perineural infiltration (p = .007). StrongCHD1loss was associated with a shorter time to PSA recurrence in the univariate (p = .04), and showed a trend to be associated with the PSA recurrence risk in the multivariate analysis (p = .058).Conclusions: The results of the present study suggest that the loss of SPOP protein expression, either alone or in combination with loss of PTEN and, on the other hand, a marked loss of theCHD1gene are very promising prognostic biomarkers in PCa.